



Excellence and Innovation
in patients care

www.recherche.unicancer.fr/en

Research is at the heart of Unicancer's action. In recent years, cancer research has proven to be a formidable field of therapeutic, technological and organisational innovation.

Pr. Jean-Yves Blay – Unicancer Président

Innovative by nature, the Centres in our network have always been at the forefront of the fight against cancer to improve patient care, by ensuring rapid access to innovations in care and research.

Sophie Beaupère – Unicancer General Director



THE UNICANCER NETWORK, A MAJOR PLAYER IN ONCOLOGY RESEARCH

The health crisis has demonstrated the need for an agile health system and a supportive environment for research and innovation.

Although the development of science, research and new technologies now makes it possible to better detect, treat and live with cancer, it remains the leading cause of death in France.

This is why cancer research is one of the foundations of the Unicancer network's ambition, which is to do everything possible to provide patients with ever earlier detection and ever more innovative and personalised treatments.

Unicancer is more than 22,000 highly qualified women and men, united, committed and driven by a common and ambitious objective: to cure cancer.

100%
dedicated to the fight
against cancer

(2021 figures)



GCS* UNICANCER RESEARCH

As the leading academic sponsor of clinical trials in oncology in Europe, Unicancer plays a leading role in cancer research.

Driven by strong values and ambitions, we have always defended the key levers of **our strategy**:

- **Intensify** prevention and screening
- **Improve** the quality of life of patients
- **Develop** artificial intelligence and data science
- **Increase** research programmes in cancers with an unfavourable prognosis




*GCS : Groupement de Coopération Sanitaire



RESEARCH IN THE UNICANCER NETWORK

- The Unicancer Research Network brings together **the 18 FCCCs**, two affiliated members and the Research Department of the Federation.

As major player in cancer research in France and internationally, Unicancer benefits from the strength of a **dynamic, mobilised and pioneering network**.



30 Active International Trials

6 Active Countries outside of France

49 Recruiting Sites outside of France

INTERNATIONAL: A FORWARD-LOOKING PRIORITY

Unicancer teams initiate and maintain collaborations with research actors at the **international level**.

Unicancer is the local representative of the EORTC in France since 2009.

In this way, we contribute to changing practices and promoting **French excellence** outside France.



This European grouping for the benefit of prostate cancer research has the ambition to conduct comparative trials in Europe to evaluate new treatments. By filling the “numerical gap” in phase III clinical trials, they are making a significant contribution to research and best practice in the treatment of genitourinary cancer. Many results have already been presented at conferences such as ESMO and ASCO.

+75,000 Samples stored

UNICANCER OPENS ITS DATA TO RESEARCH

In order to **accelerate the development of knowledge in oncology and to increase the interfaces between basic and clinical research (translational research)**, Unicancer Research provides researchers and clinicians from all institutions with access to data for their projects of interest.

In addition, the numerous ancillary research studies carried out in conjunction with clinical trials have enabled Unicancer to build up a collection of biological samples that can be associated with clinical data and thus allow reuse for research purposes, while respecting the current regulations.

190,000 Aliquots

AN AMBITIOUS DATA STRATEGY

FOCUS ON FLAGSHIP HEALTH DATA PROGRAMMES

+80,000
Cases Selected

ESMÉ is a unique real-life data collection and analysis system that centralises data on the management of patients with breast, lung and ovarian cancer in France.

unicancer



we share is a research infrastructure supported by future investment programmes dedicated to promoting and facilitating the integration of social and human sciences in cancer research, by pooling resources and skills.

ODH is the first French reference platform developed to accelerate the production and exploitation of quality real-life data. As true drug observatory, ODH should make it possible to characterise the use of therapeutic innovations in oncology.

O N C O
▶ A T A
■ H U B

THE PATIENT AT THE HEART OF OUR ACTIONS



canto is a study that aims to identify the long-term toxic effects of breast cancer treatments in order to improve the quality of life of women during and after cancer.

CANCER TOXICITIES



is an international study coordinated by

Unicancer, funded by the European Union, evaluating a new breast cancer screening strategy based on each woman's individual risk of developing the disease.

A total of 85,000 volunteer women aged between 40 and 70 who have never had breast cancer are expected to participate in the recruiting countries: France, Italy, Israel, Belgium, UK, Spain.

www.mypebs.eu

12,000
Women enrolled

627
Recruiting Partners
Countries

We maintain close and lasting partnerships with the Ligue contre le cancer and the Fondation ARC, two non-profit organisations working organisations working for cancer research.



(2021 figures)



ACCCELERATE RESEARCH AGAINST CANCER.
IMPROVE DIAGNOSTIC AND THERAPEUTIC METHODS.



101, rue de Tolbiac
75654 Paris Cedex 13
Tél. 01 44 23 04 04
unicancer@unicancer.fr

contact@recherche.unicancer.fr